Descrease article font size Increase article font size Pfizer on Wednesday forecast 2024 sales that were as much as $5 billion below Wall Street expectations due mostly to declining demand …
Pfizer on Tuesday urged investors to focus on growth in its non-COVID products such as its new RSV vaccine Abrysvo, after weak demand for its COVID-19 vaccine and treatment pushed …
Pfizer on Wednesday said the updated Pfizer-BioNTech COVID-19 vaccine expected to be used this fall elicited a strong antibody response against the highly mutated BA.2.86 subvariant of the coronavirus in …